Clinical trials: Advanced Solid Tumors With MAPK Signal Pathway Mutations
Advanced Solid Tumors With MAPK Signal Pathway Mutations
GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results
This is a multi-center, open-label, dose escalation phase I and dose expansion phase II study aimed to evaluate the safety, tolerability, PK and PD profiles as well as to observe the efficacy of GH55 in patients with MAPK mutant…
- Trial name
- NCT06310382
- Testing
- GH55
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.